Experienced in Hereditary Hemorrhagic Telangiectasia

Dr. Nina R. Shah

Hematology | Oncology
University Of California San Francisco
400 Parnassus Ave, Mcb300, 
San Francisco, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Hereditary Hemorrhagic Telangiectasia
University Of California San Francisco
400 Parnassus Ave, Mcb300, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Nina Shah is a Hematologist and an Oncologist in San Francisco, California. Dr. Shah is rated as an Experienced provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. Her top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 202 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 1 Less Insurance Carrier -

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
400 Parnassus Ave, Mcb300, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching
Clinical and Patient Reported Outcomes for Individuals with Relapsed/Refractory Multiple Myeloma Treated with Isatuximab: Real-World Insights from Patient Reported, Wearable, and Qualitative Data in the Context of Digital Health Coaching
Enrollment Status: Recruiting
Publish Date: December 11, 2024
Intervention Type: Device, Behavioral
Study Phase: Not Applicable
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 09, 2025
Intervention Type: Drug, Other, Procedure, Biological
Study Drugs: Elotuzumab, Lenalidomide, Melphalan, Natural Killer Cell Therapy, Umbilical Cord Blood-Derived Lymphocyte Therapy
Study Phase: Phase 2
Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies
Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-BCMA CAR-T Therapies
Enrollment Status: Terminated
Publish Date: January 15, 2025
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Enrollment Status: Completed
Publish Date: June 11, 2024
Intervention Type: Drug
Study Drug: STRO-001
Study Phase: Phase 1
Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab
Phase II Study of Daratumumab in Combination With Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated With Daratumumab
Enrollment Status: Terminated
Publish Date: April 30, 2024
Intervention Type: Drug, Biological
Study Drugs: Azacitidine, Daratumumab, Dexamethasone
Study Phase: Phase 2
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 22, 2023
Intervention Type: Biological
Study Drug: UCARTCS1A
Study Phase: Phase 1
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: September 21, 2023
Intervention Type: Genetic, Drug
Study Drugs: Fludarabine, Cyclophosphamide
Study Phase: Phase 1
Phase II Study of Digital Life Coaching in Multiple Myeloma Patients Undergoing Stem Cell Transplantation
Phase II Study of Digital Life Coaching in Multiple Myeloma Patients Undergoing Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: July 20, 2023
Intervention Type: Other, Behavioral
Study Phase: Not Applicable
Digital Life Coaching in Multiple Myeloma Patients Undergoing Hematopoietic Stem Cell Transplantation
Digital Life Coaching in Multiple Myeloma Patients Undergoing Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: June 04, 2021
Intervention Type: Behavioral
Study Phase: Not Applicable
View 8 Less Clinical Trials

202 Total Publications

Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Journal: Gynecologic oncology
Published: January 31, 2025
Similar Doctors
Advanced in Hereditary Hemorrhagic Telangiectasia
Dr. Andrew Leavitt
Hematology
Advanced in Hereditary Hemorrhagic Telangiectasia
Dr. Andrew Leavitt
Hematology

Ucsf Medical Group Business Services

3100 San Pablo Ave, 
Berkeley, CA 
 (11.0 miles away)
510-985-5020
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Leavitt is a Hematologist in Berkeley, California. Dr. Leavitt is rated as a Distinguished provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. His top areas of expertise are Hemophilia A, Von Willebrand Disease (VWD), Thrombocytopenia, Bone Marrow Aspiration, and Splenectomy.

Advanced in Hereditary Hemorrhagic Telangiectasia
Dr. Beth A. Martin
Hematology
Advanced in Hereditary Hemorrhagic Telangiectasia
Dr. Beth A. Martin
Hematology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (27.6 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Beth Martin is a Hematologist in Stanford, California. Dr. Martin is rated as a Distinguished provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. Her top areas of expertise are Hemophagocytic Lymphohistiocytosis, Non-Langerhans-Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Martha C. Man
Oncology | Hematology | Hematology Oncology
Experienced in Hereditary Hemorrhagic Telangiectasia
Dr. Martha C. Man
Oncology | Hematology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (27.6 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Martha Man is an Oncologist and a Hematologist in Stanford, California. Dr. Man is rated as a Distinguished provider by MediFind in the treatment of Hereditary Hemorrhagic Telangiectasia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Angiosarcoma, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Shah's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 70 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile